VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group

VolitionRx (NYSE:VNRX) was downgraded by equities researchers at Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Marketbeat reports.

Several other equities analysts also recently weighed in on VNRX. D. Boral Capital reissued a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Wednesday, November 26th. HC Wainwright dropped their price objective on shares of VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $3.17.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.28 on Wednesday. VolitionRx has a 1-year low of $0.27 and a 1-year high of $0.94. The business’s 50 day moving average is $0.44 and its two-hundred day moving average is $0.58. The stock has a market capitalization of $34.92 million, a P/E ratio of -0.79 and a beta of 1.24.

Insiders Place Their Bets

In other VolitionRx news, CEO Cameron John Reynolds acquired 110,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The stock was bought at an average price of $0.51 per share, for a total transaction of $56,100.00. Following the acquisition, the chief executive officer directly owned 2,534,847 shares in the company, valued at $1,292,771.97. The trade was a 4.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Guy Archibald Innes bought 96,153 shares of VolitionRx stock in a transaction on Tuesday, October 14th. The stock was acquired at an average price of $0.51 per share, for a total transaction of $49,038.03. Following the purchase, the director owned 1,062,967 shares of the company’s stock, valued at approximately $542,113.17. This trade represents a 9.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 289,229 shares of company stock valued at $146,557. 10.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On VolitionRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lagoda Investment Management L.P. grew its stake in VolitionRx by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock worth $8,476,000 after acquiring an additional 782,000 shares in the last quarter. Armistice Capital LLC raised its stake in shares of VolitionRx by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock valued at $6,367,000 after acquiring an additional 887,351 shares in the last quarter. Citadel Advisors LLC boosted its holdings in shares of VolitionRx by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the period. Silverberg Bernstein Capital Management LLC grew its stake in VolitionRx by 15.6% in the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after purchasing an additional 31,300 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new position in VolitionRx in the second quarter worth approximately $52,000. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.